7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086

Araujo, James L.; Mathew, Paul; Armstrong, Amy J.; Braud, Edward L.; Posadas, Edwin M.; Lonberg, Mathew; Gallick, Gary E.; Trudel, Géralyn C.; Paliwal, Prashni; Logothetis, C.

doi:10.1016/s1359-6349(09)71406-5

Cited by 13 publications

(11 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…81 Another phase II trial investigated the combination of dasatinib 100 mg daily plus docetaxel 75 mg/m 2 every 21 days in 31 chemotherapy-naïve men with metastatic CRPC. 82 Of those enrolled, 21 patients had measurable disease by RECIST criteria and 16 of these patients did not show progression after more than 21 weeks. Furthermore, 30 of 31 patients had a best response of improved (32%) or stable disease (65%) after 6 weeks or more, which was objectively evidenced by bone scan.…”

Section: Dasatinibmentioning

confidence: 99%

“…This is much less than the 51% reported in the higher dosing trials previously addressed. 82 These phase II studies have paved the way for a clinical trial currently recruiting patients to assess dasatinib's effect in metastatic CRPC. 83 This is a randomized, double-blind, phase III trial comparing docetaxel combined with dasatinib (100 mg daily) to docetaxel combined with placebo in chemotherapy-naïve patients with CRPC.…”

Section: Dasatinibmentioning

confidence: 99%

See 1 more Smart Citation

Emerging novel therapies in the treatment of castrate-resistant prostate cancer

Abdulla

Kapoor

2013

CUAJ

View full text Add to dashboard Cite

The treatment options for patients with castration-resistant prostate cancer (CRPC), until very recently, only included docetaxel. In the past 10 months, newly Federal Drug Administration (FDA) approved agents in the United States have shown survival benefit for patients with CRPC. This review takes a closer look at these newer agents: sipuleucel-T (immune therapy) and cabazitaxel (cytotoxic therapy). We also review the evidence supporting the FDA's approval of denosumab (bone-targeted therapy) as a treatment option for men with CRPC and bony metastases. Newer agents currently being investigated in phase III clinical trials for their potential role in metastatic CRPC are also reviewed. These agents include abiraterone (hormonal therapy), TAK-700 (hormonal therapy), MDV3100 (hormonal therapy), ipilimumab (immune therapy), zibotentan (endothelin-A receptor antagonist) and dasatinib (tyrosine kinase inhibitor). As ongoing studies using all the aforementioned agents continue to evolve, our understanding of how and where these agents fit into the treatment paradigm for patients with CRPC will become clearer. RésuméLes options thérapeutiques des patients atteints d'un cancer de la prostate résistant à la castration (CPRC), jusqu'à tout récemment, ne comprenaient que le docetaxel. Au cours des 10 derniers mois, de nouveaux agents approuvés par la Food and Drug Administration (FDA) des États-Unis ont montré un avantage lié à la survie chez les patients atteints d'un CPRC. Nous examinons ici plus étroite-ment ces nouveaux agents : le sipuleucel-T (immunothérapie) et le cabazitaxel (traitement cytotoxique). Nous passons aussi en revue les données étayant l'approbation par la FDA du dénosumab (traitement ciblant les cellules osseuses) comme option thérapeutique chez les hommes atteints d'un cancer de la prostate résistant à la castration avec métastases osseuses. Les nouveaux agents en cours d'études cliniques de phase III en raison de leur rôle potentiel dans le traitement du CPRC métastatique sont aussi examinés. Ces agents incluent l'abiratérone (hormonothérapie), le TAK-700 (hormonothérapie), le MDV3100 (hormonothérapie), l'ipilimumab (immunothérapie), le zibotentan (antagoniste des récepteurs de l'endothéline-A) et le dasatinib (inhibiteur de la tyrosine-kinase). À mesure que les études en cours sur ces agents continuent de progresser, notre compréhen-sion du rôle et de l'usage de ces agents dans le paradigme théra-peutique des patients atteints de CPRC s'approfondira.

show abstract

Section: Dasatinibmentioning

confidence: 99%

Section: Dasatinibmentioning

confidence: 99%

Emerging novel therapies in the treatment of castrate-resistant prostate cancer

Abdulla

Kapoor

2013

CUAJ

View full text Add to dashboard Cite

show abstract

“…Several trials in the pre-and post-chemotherapy settings are ongoing, with the objective of delaying progression and the need for chemotherapy and of improving overall survival. Novel agents such as Src and clusterin inhibitors are also being tested in phase iii trials in combination with docetaxel in the first-line setting 10,[31][32][33][34] . Because crpc remains an incurable and ultimately fatal illness, participation in clinical trials at all stages of the disease remain paramount.…”

Section: Clinical Trials and Future Directionsmentioning

confidence: 99%

Management of Castration-Resistant Prostate Cancer: A Global Approach

Saad

2012

Current Oncology

View full text Add to dashboard Cite

Treatment options for castration-resistant prostate cancer (CRPC) have evolved since the start of the 2000s, with most of the new effective therapies appearing since 2010. In 2004, docetaxel was the first chemotherapeutic agent to improve survival in CRPC, but little else was available once patients recurred. Since 2010, four new options have been shown to improve survival in patients with refractory or recurring disease after docetaxel. In the management of bone metastases, two bone-targeted therapies have been shown to reduce the risk of bone complications, and they are part of the overall management strategy in CRPC patients. Therapeutic options before chemotherapy have shown promising results and may soon become available in Canada. The present article reviews the treatment options that have shown to be effective in CRPC and also some of the ongoing work in the field.

show abstract

“…Although monotherapy with the src inhibitors dasatinib and saracatinib shows modest efficacy [31,32], high rates of objective tumor response with the combination of dasatinib and docetaxel [33] are the basis of an ongoing randomized phase 3 study of docetaxel and dasatinib or placebo in metastatic CRPC.…”

Section: ) Osteoclast Targetingmentioning

confidence: 99%

Optimal Management of Bone Metastases in Prostate Cancer

Aljumaily

Mathew

2011

Curr Oncol Rep

View full text Add to dashboard Cite

The biological basis of the selective outgrowth of disseminated prostate cancer cells within the hematopoietic bone microenvironment remains a compelling biological mystery. A major proportion of the morbidity and mortality related to prostate cancer can be traced to the burden of bone metastases. The optimal management of bone health in men with prostate cancer requires control of the underlying epithelial neoplasm, attenuation of the subverted bone remodeling process that accompanies disease progression, reduction in the bone complications of disease-directed therapy, and management of co-existing comorbidities that enhance bone fragility. While bone-homing radioisotopes, bisphosphonates, and RANK ligand inhibitors have demonstrated reduction in bone pain and/or other skeletal-related events, further advances into definitive improvements in survival and/or global quality of life are required. A deeper understanding of the biology of bone metastases will likely facilitate a bone-directed therapeutic approach toward a major impact on the survival of men with this important disease.

show abstract

7028 Dasatinib and docetaxel combination treatment for patients with metastatic castration-resistant prostate cancer (CRPC): analysis of Study CA180–086

Cited by 13 publications

References 0 publications

Emerging novel therapies in the treatment of castrate-resistant prostate cancer

Emerging novel therapies in the treatment of castrate-resistant prostate cancer

Management of Castration-Resistant Prostate Cancer: A Global Approach

Optimal Management of Bone Metastases in Prostate Cancer

Contact Info

Product

Resources

About